The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition

International Journal of Oncology

Volumn 44, Issue 3, 2014, Pages 735-744

  Xia, Qing ^a,b   Cai, Yuchen ^a   Peng, Roujun ^a   Wu, Guosheng ^c   Shi, Yanxia ^a   Jiang, Wenqi ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^c UNIVERSITY OF MACAU   (Macao)

Author keywords

BRCA1; Breast cancer; Cyclin dependent kinase 1; Poly (ADP ribose) polymerase inhibitor

Indexed keywords

CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; RO 3306; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER CELL; CANCER CELL; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; HUMAN; HUMAN CELL; MONOTHERAPY; PRIORITY JOURNAL;

BRCA1 PROTEIN; CDC2 PROTEIN KINASE; CELL LINE, TUMOR; DNA DAMAGE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMOLOGOUS RECOMBINATION; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; QUINOLINES; THIAZOLES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84896710228     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2240     Document Type: Article

References (35)

1. Gucalp A and Traina TA: Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract 2011: 696208, 2011.
2. Moynahan ME, Chiu JW, Koller BH and Jasin M: Brca1 controls homology-directed DNA repair. Mol Cell 4: 511-518, 1999.
3. Zhang J and Powell SN: The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 3: 531-539, 2005.
4. Hartman AR and Ford JM: BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet 32: 180-184, 2002.
5. Alli E, Sharma VB, Sunderesakumar P and Ford JM: Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 69: 3589-3596, 2009.
6. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC and Ashworth A: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66: 8109-8115, 2006.
7. Ashworth A: A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26: 3785-3790, 2008.
8. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M and Carmichael J: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235-244, 2010.
9. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH and de Bono JS: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134, 2009.
10. Wooster R and Weber BL: Breast and ovarian cancer. N Engl J Med 348: 2339-2347, 2003.
11. Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-166, 2009.
12. Morgan DO: Principles of CDK regulation. Nature 374: 131-134, 1995.
13. Vassilev LT, Tovar C, Chen S, Knezevic D, Zhao X, Sun H, Heimbrook DC and Chen L: Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci USA 103: 10660-10665, 2006.
14. Goga A, Yang D, Tward AD, Morgan DO and Bishop JM: Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 13: 820-827, 2007.
15. Kojima K, Shimanuki M, Shikami M, Andreeff M and Nakakuma H: Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci 100: 1128-1136, 2009.
16. Johnson N, Cai D, Kennedy RD, Pathania S, Arora M, Li YC, D'Andrea AD, Parvin JD and Shapiro GI: Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol Cell 35: 327-339, 2009.
17. Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK and Shapiro GI: Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 17: 875-882, 2011.
18. Gartner EM, Burger AM and Lorusso PM: Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future. Cancer J 16: 83-90, 2010.
19. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M and Bonner WM: A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 10: 886-895, 2000.
20. Turner NC and Reis-Filho JS: Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25: 5846-5853, 2006.
21. Gudmundsdottir K and Ashworth A: The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25: 5864-5874, 2006.
22. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM and Ding W: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994.
23. Amé JC, Spenlehauer C and de Murcia G: The PARP superfamily. Bioessays 26: 882-893, 2004.
24. Turner N, Tutt A and Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4: 814-819, 2004.
25. Ira G, Pellicioli A, Balijja A, Wang X, Fiorani S, Carotenuto W, Liberi G, Bressan D, Wan L, Hollingsworth NM, Haber JE and Foiani M: DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1. Nature 431: 1011-1017, 2004.
26. Santamaría D, Barrière C, Cerqueira A, Hunt S, Tardy C, Newton K, Cáceres JF, Dubus P, Malumbres M and Barbacid M: Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448: 811-815, 2007.
27. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767, 2011.
28. Kimbung S, Biskup E, Johansson I, Aaltonen K, Ottosson-Wadlund A, Gruvberger-Saal S, Cunliffe H, Fadeel B, Loman N, Berglund P and Hedenfalk I: Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition. Cancer Lett 319: 232-241, 2012.
29. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ and Curtin NJ: Therapeutic potential of poly(ADP-ribose) polymerase inhibito AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 103: 334-346, 2011.
30. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ and Ashworth A: Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1: 315-322, 2009.
31. Inbar-Rozensal D, Castiel A, Visochek L, Castel D, Dantzer F, Izraeli S and Cohen-Armon M: A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. Breast Cancer Res 11: R78, 2009.
32. Payton M, Chung G, Yakowec P, Wong A, Powers D, Xiong L, Zhang N, Leal J, Bush TL, Santora V, Askew B, Tasker A, Radinsky R, Kendall R and Coats S: Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Res 66: 4299-4308, 2006.
33. Gao LL, Li FR, Jiao P, Yang MF, Zhou XJ, Si YH, Jiang WJ and Zheng TT: Paris chinensis dioscin induces G2/M cell cycle arrest and apoptosis in human gastric cancer SGC-7901 cells. World J Gastroenterol 17: 4389-4395, 2011.
34. Levine B and Klionsky DJ: Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6: 463-477, 2004.
35. Cuervo AM: Autophagy: in sickness and in health. Trends Cell Biol 14: 70-77, 2004.